Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation and will be responsible for registering, importing, and commercialising VOLT01 in the MEA region
Tabuk Pharmaceutical Manufacturing Company has signed an exclusive licence and distribution agreement with US’ Levolta Pharmaceuticals to commercialise an investigational osteoarthritis (OA) therapy in Middle East and Africa.
Pennsylvania-based Levolta Pharmaceuticals has entered into an exclusive licensing and distribution agreement with Saudi Arabia company, Tabuk Pharmaceutical Manufacturing Company to start commercializing a therapy for osteoarthritis (OA).
Levolta has entered into an exclusive licensing and distribution agreement with Tabuk for commercialising VOLT01 in the Middle East and Africa (MEA) region.